Harmine alleviates atherogenesis by inhibiting disturbed flow‐mediated endothelial activation via protein tyrosine phosphatase PTPN14 and YAP

British Journal of Pharmacology
2021.0

Abstract

BACKGROUND AND PURPOSE: Disturbed flow induces endothelial dysfunction and contributes to uneven distribution of atherosclerotic plaque. Emerging evidence suggests that harmine, a natural constituent of extracts of Peganum harmala, has potent beneficial activities. Here, we investigated if harmine has an atheroprotective role under disturbed flow and the underlying mechanism. EXPERIMENTAL APPROACH: Mice of ApoE(-/-) , LDLR(-/-) , and endothelial cell (EC)-specific overexpression of yes-associated protein (YAP) in ApoE(-/-) background were fed with a Western diet and given harmine for 4 weeks. Atherosclerotic lesion size, cellular composition, and expression of inflammatory genes in the aortic roots were assessed. HUVECs were treated with oscillatory shear stress (OSS) and harmine and also used for proteomic analysis. KEY RESULTS: Harmine retarded atherogenesis in both ApoE(-/-) and LDLR(-/-) mice by inhibiting the endothelial inflammatory response. Mechanistically, harmine blocked OSS-induced YAP nuclear translocation and EC activation by reducing phosphorylation of YAP at Y357. Overexpression of endothelial YAP blunted the beneficial effects of harmine in mice. Proteomic study revealed that protein tyrosine phosphatase non-receptor type 14 (PTPN14) could bind to YAP. Moreover, harmine increased PTPN14 expression by stabilizing its protein level and inhibiting its degradation in proteasomes. PTPN14 knockdown blocked the effects of harmine on YAP(Y357) and EC activation. Finally, overexpression of PTPN14 mimicked the effects of harmine and ameliorated atherosclerosis, and knockdown of PTPN14 blunted the atheroprotective effects of harmine and accelerated atherosclerosis, in a partial ligation mouse model. CONCLUSION AND IMPLICATIONS: Harmine alleviated OSS-induced EC activation via a PTPN14/YAP(Y357) pathway and had a potent atheroprotective role. CI - (c) 2021 The British Pharmacological Society.

Knowledge Graph

Similar Paper

Harmine alleviates atherogenesis by inhibiting disturbed flow‐mediated endothelial activation via protein tyrosine phosphatase PTPN14 and YAP
British Journal of Pharmacology 2021.0
Harmine is an effective therapeutic small molecule for the treatment of cardiac hypertrophy
Acta Pharmacologica Sinica 2022.0
Harmine Inhibits Multiple TLR-Induced Inflammatory Expression through Modulation of NF-κB p65, JNK, and STAT1
Life 2022.0
Harmine is an inflammatory inhibitor through the suppression of NF-κB signaling
Biochemical and Biophysical Research Communications 2017.0
Harmine Alleviates Titanium Particle-Induced Inflammatory Bone Destruction by Immunomodulatory Effect on the Macrophage Polarization and Subsequent Osteogenic Differentiation
Frontiers in Immunology 2021.0
Harmine Acts as an Indirect Inhibitor of Intracellular Protein Aggregation
ACS Omega 2020.0
Resveratrol restores lysophosphatidylcholine‐induced loss of endothelium‐dependent relaxation in rat aorta tissue coinciding with inhibition of extracellular‐signal‐regulated protein kinase activation
Phytotherapy Research 2010.0
A preliminary study on the neurotoxic mechanism of harmine in Caenorhabditis elegans
Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 2021.0
Pharmacological effects of harmine and its derivatives: a review
Archives of Pharmacal Research 2020.0
Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor
Journal of Medicinal Chemistry 2020.0